Molbio Diagnostics Limited, a leader in point-of-care molecular diagnostics, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, headquartered in Goa, is known for its proprietary 'Truenat' platform which delivers rapid diagnostic results in resource-limited settings. The IPO is scheduled to open on 10-Aug-2026 and close on 12-Aug-2026, with listing expected on 17-Aug-2026. While the issue size and price band are yet to be finalized, the filing provides deep insights into the company's strong financial growth and strategic positioning in the global diagnostics market.

Company Overview

Molbio Diagnostics operates as a point-of-care diagnostics company focusing on molecular testing for infectious and non-communicable diseases. Its flagship product, the Truenat platform, comprises the Trueprep (nucleic acid extraction device) and Truelab Analyzer (portable PCR analyzer). This closed-system design ensures recurring revenue through test kit sales.

Key operational highlights include:

• Disease Coverage: Tests for 30 diseases with 43 assays as of March 31, 2026, including Tuberculosis (TB), COVID-19, Hepatitis B & C, HIV, and HPV.
• Manufacturing: Facilities located in Goa (Unit I & II) and Visakhapatnam. Note that all manufacturing facilities and offices are on leased land.
• Market Position: Operates in an oligopolistic market with high entry barriers, requiring 13 years of R&D for ICMR certification.
• Subsidiaries: Holds stakes in Bigtec (100%, R&D), Prognosys Medical Systems (65.47%, Radiology), and OptraScan INC (60.00%, Digital Pathology).

Offer Details

The specific issue size, price band, and lot size are not available in the DRHP and will be disclosed in the final Red Herring Prospectus (RHP). However, the timeline and objects of the issue are defined:

Objects of the Issue: The proceeds will primarily fund capital expenditure:

1. R&D Facility: ₹105.53 Crores for a Center of Excellence operated by Bigtec (~150,000 sq. ft.).
2. Automation: ₹72.28 Crores for plant, machinery, and equipment at Goa and Visakhapatnam units.
3. General Corporate Purposes: Up to 25% of gross proceeds.

Total identified use of proceeds is ₹177.81 Crores.

Financial Highlights

Molbio Diagnostics has demonstrated robust top-line growth over the past three years. Revenue from operations grew at a 3-year CAGR of approximately 31.40%.

While revenue surged by 41.68% YoY in FY2026, PAT growth decelerated to 18.44% YoY, leading to margin compression. Operating cash flow declined sharply from ₹287.10 Cr in FY2025 to ₹50.39 Cr in FY2026, despite strong revenue performance.

Risk Factors

Investors should note several material risks highlighted in the DRHP:

1. High Government Dependency: 84.56% of FY2026 revenue was derived from Indian central/state governments and international aid agencies. Policy changes could significantly impact sales.
2. TB Test Kit Concentration: Tuberculosis diagnostic kits contributed 70.20% of revenue in FY2026, an increase from 62.40% in FY2024. Decline in TB kit demand poses a significant risk.
3. Customer Concentration: The top 10 customers accounted for 83.26% of revenue in FY2026.
4. Working Capital & Debt: Total outstanding borrowings stood at ₹4,225.01 million as of May 31, 2026. Non-current liabilities surged by 436.86% YoY in FY2026.
5. Subsidiary Losses: Key subsidiaries, including OptraScan INC (loss of ₹111.42 million in FY2026), have incurred losses.

Valuation & Peer Comparison

Peer comparison data and valuation multiples (P/E, P/B) are not available as the price band has not been announced. The global Point-of-Care Testing (POCT) market is projected to grow from USD 29.3 billion in 2025 to USD 67.1 billion by 2030 at a CAGR of 17.90%, providing a large addressable market for Molbio.

Bottom Line

Molbio Diagnostics presents a compelling growth story with a proprietary technology platform and strong revenue expansion. However, investors must weigh this against high concentration risks in government funding and TB tests, along with margin compression and rising debt levels. The final valuation will depend on the price band announced in the RHP.